Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Radiopharm Theranostics.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Opthea up 13pc on $85m funding from giant investment firm Carlyle, new investor
Health & Biotech
ASX Health Stocks: Next Science jumps almost 10pc after XPERIENCE study published in science journal
Health & Biotech
ASX Health Stocks: Cleo Diagnostics delivers milestones, Radiopharm to begin Phase 1 study
Explainers
ASX cancer stocks guide: Here’s everything you need to know
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Health & Biotech
ASX biotechs are looking up, and the FDA breakthroughs are starting to flow
News
In Case You Missed It: Lithium does the heavy lifting today
Health & Biotech
ASX Health Stocks: Tissue Repair and Radiopharm jump double digits after US FDA meetings
Health & Biotech
Orphan drug designation has a direct impact on drug pricing for these pharma players
Health & Biotech
ASX Health Stocks: The US FDA will pay a visit to Cyclopharm’s facility in NSW
Health & Biotech
ASX Health Stocks: Clarity Pharma shows effectiveness in diagnosing prostate lesions in Phase 1 trial
Health & Biotech
Which ASX stocks are on the path from FDA to clinical trial in 2023?
Health & Biotech
ASX Tech & Biotech: Kleos launches new geospatial intelligence product, Radiopharm scores FDA approval
Experts
THE SUNDAY ROAST: The ASX small caps that lit a fire under Stockhead’s experts this week.
Experts
MoneyTalks: Two reasons why today’s Aussie biotech sector is like the ’90s scramble for beachside property
Health & Biotech
ASX Biotech Stocks: Neurotech reports positive paediatric autism results and Arovella to close Perth R&D facility
Health & Biotech
